- Home
- EML vs LCTX Comparison
EML vs LCTX Comparison
Compare EML & LCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EML
- LCTX
- Stock Information
- Founded
- EML 1858
- LCTX 1990
- Country
- EML United States
- LCTX United States
- Employees
- EML N/A
- LCTX N/A
- Industry
- EML Industrial Machinery/Components
- LCTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- EML Consumer Discretionary
- LCTX Health Care
- Exchange
- EML Nasdaq
- LCTX Nasdaq
- Market Cap
- EML 191.3M
- LCTX 110.2M
- IPO Year
- EML N/A
- LCTX N/A
- Fundamental
- Price
- EML $26.66
- LCTX $0.55
- Analyst Decision
- EML
- LCTX Strong Buy
- Analyst Count
- EML 0
- LCTX 5
- Target Price
- EML N/A
- LCTX $4.80
- AVG Volume (30 Days)
- EML 11.4K
- LCTX 2.9M
- Earning Date
- EML 11-01-2024
- LCTX 03-06-2025
- Dividend Yield
- EML 1.66%
- LCTX N/A
- EPS Growth
- EML N/A
- LCTX N/A
- EPS
- EML N/A
- LCTX N/A
- Revenue
- EML $284,461,286.00
- LCTX $8,719,000.00
- Revenue This Year
- EML N/A
- LCTX N/A
- Revenue Next Year
- EML N/A
- LCTX $41.15
- P/E Ratio
- EML $13.23
- LCTX N/A
- Revenue Growth
- EML 7.70
- LCTX N/A
- 52 Week Low
- EML $22.63
- LCTX $0.48
- 52 Week High
- EML $35.78
- LCTX $1.61
- Technical
- Relative Strength Index (RSI)
- EML 43.93
- LCTX 47.26
- Support Level
- EML $25.31
- LCTX $0.51
- Resistance Level
- EML $26.90
- LCTX $0.60
- Average True Range (ATR)
- EML 0.69
- LCTX 0.04
- MACD
- EML 0.00
- LCTX 0.01
- Stochastic Oscillator
- EML 54.66
- LCTX 53.85
About EML Eastern Company (The)
The Eastern Co manages industrial businesses that design, manufacture, and sell engineered solutions to industrial markets. The company manages the financial, operational, and strategic performance of its businesses to increase cash generation, operating earnings, and long-term shareholder value. It operates in the United States and Other Countries and generates the majority of its revenue from the United States.
About LCTX Lineage Cell Therapeutics Inc.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.